251 related articles for article (PubMed ID: 32557339)
1. Capmatinib: First Approval.
Dhillon S
Drugs; 2020 Jul; 80(11):1125-1131. PubMed ID: 32557339
[TBL] [Abstract][Full Text] [Related]
2. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
3. Capmatinib in
Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795
[TBL] [Abstract][Full Text] [Related]
5. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
[TBL] [Abstract][Full Text] [Related]
6. Capmatinib for non-small cell lung cancer.
Alzofon N; Jimeno A
Drugs Today (Barc); 2021 Jan; 57(1):17-25. PubMed ID: 33594387
[TBL] [Abstract][Full Text] [Related]
7. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
Kanemura H; Takeda M; Shimizu S; Nakagawa K
Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
[TBL] [Abstract][Full Text] [Related]
9. Capmatinib for the treatment of non-small cell lung cancer.
Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
[No Abstract] [Full Text] [Related]
10. MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.
Zhu K; Lv Z; Xiong J; Zheng H; Zhang S; Jin H; Yu L; Li Z; Zhang J; Li C; Liang P
Aging (Albany NY); 2021 Feb; 13(5):6890-6903. PubMed ID: 33621951
[TBL] [Abstract][Full Text] [Related]
11. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.
Kim S; Kim TM; Kim DW; Kim S; Kim M; Ahn YO; Keam B; Heo DS
Cancer Res Treat; 2019 Jul; 51(3):951-962. PubMed ID: 30309221
[TBL] [Abstract][Full Text] [Related]
12. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a
Cai B; Zhou ZY; Xue W; Hazra NC; Singh M; Mishra D; Brixner D; Oderda G; Biskupiak J
J Med Econ; 2021; 24(1):131-139. PubMed ID: 33397178
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
14. Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation.
Vanderick A; Colinet B
Acta Clin Belg; 2024 Apr; 79(2):148-151. PubMed ID: 38494868
[TBL] [Abstract][Full Text] [Related]
15. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
Tseng LW; Chang JW; Wu CE
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109
[TBL] [Abstract][Full Text] [Related]
16. Suppression of MET Signaling Mediated by Pitavastatin and Capmatinib Inhibits Oral and Esophageal Cancer Cell Growth.
Xu B; Muramatsu T; Inazawa J
Mol Cancer Res; 2021 Apr; 19(4):585-597. PubMed ID: 33443139
[TBL] [Abstract][Full Text] [Related]
17. Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.
Seto T; Ohashi K; Sugawara S; Nishio M; Takeda M; Aoe K; Moizumi S; Nomura S; Tajima T; Hida T
Cancer Sci; 2021 Apr; 112(4):1556-1566. PubMed ID: 33506571
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors.
Moreno V; Greil R; Yachnin J; Majem M; Wermke M; Arkenau HT; Basque JR; Nidamarthy PK; Kapoor S; Cui X; Giovannini M
Clin Ther; 2021 Jun; 43(6):1092-1111. PubMed ID: 34053700
[TBL] [Abstract][Full Text] [Related]
19. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Wu YL; Zhang L; Kim DW; Liu X; Lee DH; Yang JC; Ahn MJ; Vansteenkiste JF; Su WC; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan DSW
J Clin Oncol; 2018 Nov; 36(31):3101-3109. PubMed ID: 30156984
[TBL] [Abstract][Full Text] [Related]
20. Tepotinib: First Approval.
Markham A
Drugs; 2020 Jun; 80(8):829-833. PubMed ID: 32361823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
